CELLICON VALLEY Trademark

Trademark Overview


On Wednesday, July 27, 2022, a trademark application was filed for CELLICON VALLEY with the United States Patent and Trademark Office. The USPTO has given the CELLICON VALLEY trademark a serial number of 97522048. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, August 12, 2024. This trademark is owned by CENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC. The CELLICON VALLEY trademark is filed in the Treatment & Processing of Materials Services, Computer & Software Services & Scientific Services, Personal, and Legal & Social Services categories with the following description:

Manufacturing services for others in the fields of pharmaceutical preparations, biopharmaceutical preparations, biologics, drug products, DNA plasmids, advanced therapeutic medicinal products (ATMPs), principally cell and gene therapies intended for research, clinical and commercial use in humans for gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; manufacturing services for others in the fields of mammalian cell banks, plasmids, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; manufacturing process consulting; production of cell lines for others using lentivirus technology

Regulatory compliance consulting in the fields of pharmaceuticals, medicines, biopharmaceuticals, and gene therapy

Research and development services in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; consulting services in the fields of research and development for gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; research and development of new products for others; process development services in the nature of research and development of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; scientific research and technical research services in the field of production of cell lines for others using lentivirus technology; scientific research and technical research services relating to producing, assaying and purifying recombinant or manipulated lentivirus; Scientific and technical consulting services relating to producing, assaying, and purifying adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in hum...
cellicon valley

General Information


Serial Number97522048
Word MarkCELLICON VALLEY
Filing DateWednesday, July 27, 2022
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, August 12, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 16, 2023

Trademark Statements


Goods and ServicesManufacturing services for others in the fields of pharmaceutical preparations, biopharmaceutical preparations, biologics, drug products, DNA plasmids, advanced therapeutic medicinal products (ATMPs), principally cell and gene therapies intended for research, clinical and commercial use in humans for gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; manufacturing services for others in the fields of mammalian cell banks, plasmids, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; manufacturing process consulting; production of cell lines for others using lentivirus technology
Goods and ServicesRegulatory compliance consulting in the fields of pharmaceuticals, medicines, biopharmaceuticals, and gene therapy
Goods and ServicesResearch and development services in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; consulting services in the fields of research and development for gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; research and development of new products for others; process development services in the nature of research and development of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; scientific research and technical research services in the field of production of cell lines for others using lentivirus technology; scientific research and technical research services relating to producing, assaying and purifying recombinant or manipulated lentivirus; Scientific and technical consulting services relating to producing, assaying, and purifying adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; advisory services relating to research and development of gene therapy products and biopharmaceuticals; manufacturing support services for others, namely, cGMP (Current Good Manufacturing Practice) quality control testing in support of biopharmaceutical development and ยท manufacturing; quality control for others; quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; material testing; product quality testing; scientific laboratory services; scientific research

Classification Information


International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code6 - Active
Class Status DateThursday, August 18, 2022
Primary Code040
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, August 18, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class045 - Legal services; security services for the protection of property and individuals; personal and social services rendered by others to meet the needs of individuals.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, August 18, 2022
Primary Code045
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressKING OF PRUSSIA, PA 19406

Party NameCENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressKING OF PRUSSIA, PA 19406

Trademark Events


Event DateEvent Description
Saturday, July 30, 2022NEW APPLICATION ENTERED
Thursday, August 18, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, March 28, 2023NON-FINAL ACTION WRITTEN
Monday, March 27, 2023ASSIGNED TO EXAMINER
Tuesday, March 28, 2023NON-FINAL ACTION E-MAILED
Tuesday, March 28, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, April 12, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, April 12, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, April 12, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, April 13, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 26, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 16, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 11, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, November 17, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, May 16, 2023PUBLISHED FOR OPPOSITION
Friday, November 17, 2023SOU EXTENSION 1 FILED
Friday, November 17, 2023SOU EXTENSION 1 GRANTED
Tuesday, November 21, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 12, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, August 12, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED